IP Library Granted Patent US 8,227,430
Granted Patent B2
US 8,227,430 · App. 12/676,291 · Granted Jul 24, 2012

Injectable, injection solution, and injection kit preparation

Assignee: Meiji Seika Pharma Co., Ltd
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,227,430
App. No.
12/676,291
Granted
Jul 24, 2012
Kind
B2
Abstract

Provided is an injectable comprising: an anthracycline antineoplastic antibiotic; and at least one acid amide selected from the group consisting of nicotinic acid amide, isonicotinic acid amide and gentisic acid ethanolamide.

Claims (15)

1. An injectable composition comprising:

an anthracycline antineoplastic antibiotic; and

at least one acid amide selected from the group consisting of nicotinic acid amide, isonicotinic acid amide and gentisic acid ethanolamide in an amount sufficient to dissolve the antibiotic in a dissolution solution faster than if the acid amide were not present.

2. The injectable composition according to claim 1 , wherein the anthracycline antineoplastic antibiotic is at least one substance selected from the group consisting of aclarubicin hydrochloride, amrubicin hydrochloride, idarubicin hydrochloride, epirubicin hydrochloride, daunorubicin hydrochloride, doxorubicin hydrochloride, pirarubicin hydrochloride and mitoxantrone hydrochloride.

3. The injectable composition according to claim 1 , wherein a content of the acid amide is 0.75 mg to 12.5 mg per mg (titer) of the anthracycline antineoplastic antibiotic.

4. An injection solution comprising:

an anthracycline antineoplastic antibiotic;

at least one acid amide selected from the group consisting of nicotinic acid amide, isonicotinic acid amide and gentisic acid ethanolamide in an amount sufficient to dissolve the antibiotic in a dissolution solution faster than if the acid amide were not present; and

the dissolution solution.

5. An injection kit preparation comprising:

a freeze-dried injectable of an anthracycline antineoplastic antibiotic; and

a dissolution solution containing at least one acid amide selected from the group consisting of nicotinic acid amide, isonicotinic acid amide and gentisic acid ethanolamide in an amount sufficient to dissolve the antibiotic in the dissolution solution faster than if the acid amide were not present.

6. An injection kit preparation comprising:

a freeze-dried injectable of an anthracycline antineoplastic antibiotic; and

a container filled with at least one acid amide selected from the group consisting of nicotinic acid amide, isonicotinic acid amide and gentisic acid ethanolamide in an amount sufficient to dissolve the antibiotic in a dissolution solution faster than if the acid amide were not present.

Assignments (2)
CHANGE OF NAME Recorded Jun 20, 2012
From: MEIJI SEIKA KAISHA, LTD.
To: MEIJI SEIKA PHARMA CO., LTD.
Reel/Frame 028415/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 9, 2010
From: YOSHIZAWA, TERUHISA; MIYOSHI, AKIKO; OTA, MASATO
To: MEIJI SEIKA KAISHA, LTD.
Reel/Frame 024048/0174 →
Priority Claims (1)
JP 2007-228516 · Sep 4, 2007 · national
Continuity (1)
Related Publication 20100173862A1 · Jul 8, 2010